John K. Stroh
Verified
I have over 30 years of experience in senior management, operations, finance, investment banking and M&A, primarily in the Medical Technology, Life Science and the Healthcare services fields. Prior to Tellson, I was CEO of Nanospectra, LeuKoDx and Purewick which was sold to Bard in 2017. Prior to this I was President, CEO and Director of NeoMatrix LLC, a breast cancer risk assessment medical device company based in Irvine, California. Prior to NeoMatrix I was COO & CFO, of Kadmus Pharmaceuticals, a Pharmaceutical Development company that focused on the treatment of CNS disorders using cannabanoids to target internal receptors. The company was sold to Schering-Plough at 50 times the original investment.
In addition to my extensive background in capital raising ( over $2B for client companies) I have also been engaged in over 100 M&A advisory assignments. Through my Investment Banking experience at John Nuveen ,Piper Jaffray, Kidder Peabody, Roth Capital and other Investment Banks I have acquired significant experience in Raising Capital as well as M&A advisory work. Industries focus includes Life Sciences, Medical Device, Healthcare IT and Healthcare Services
John Stroh

email: johnkstroh@gmail.com
mobile: 714.401.0915